Stifel lowered the firm’s price target on Amwell (AMWL) to $8 from $10 and keeps a Hold rating on the shares. Q1 revenue outperformed due to lower-than-forecasted customer churn, mix shift within AMG visits towards specialty programs, and the timing of professional service-based revenue, but Q2 revenue guidance was below consensus due to delays in the DHA rollout and lower professional services revenue, the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- American Well’s Hold Rating Amid Contract Delays and Optimistic Cash Flow Outlook
- Amwell Reports Strong Q1 2025 Financial Results
- Hold Rating Maintained for American Well Amid Revenue Growth and Contract Uncertainties
- Amwell backs FY25 revenue view $250M-$260M, consensus $255.06M
- Amwell reports Q1 EPS ($1.19), consensus ($1.88)